Editorial: Systems clinical pharmacology

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 1, 2010, Pages 3-6

  Atkinson Jr , A J ^a   Lyster, P M ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; BIOLOGICAL MARKER;

CLINICAL PHARMACOLOGY; DRUG INDUSTRY; DRUG RESEARCH; EDITORIAL; PRIORITY JOURNAL; SYSTEM ANALYSIS; DRUG DEVELOPMENT; SYSTEMS BIOLOGY;

BIOLOGICAL MARKERS; DRUG DISCOVERY; PHARMACOLOGY, CLINICAL; SYSTEMS BIOLOGY;

EID: 77953743760     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.88     Document Type: Editorial

References (20)

1. Academy of Medical Sciences and The Royal Academy of Engineering Working Group. Systems Biology: A Vision for Engineering and Medicine http://www3. imperial.ac.uk/pls/portallive/docs/1/23357696.pdf.
2. Arrell, D.K. & Terzic, A. Network systems biology for drug discovery. Clin. Pharmacol. Ther. 88, 120-125 (2010).
3. Kohl, P., Crampin, E.J., Quinn, T.A. & Noble, D. Systems biology: an approach. Clin. Pharmacol. Ther. 88, 25-33 (2010).
4. Van der Greef, J. & McBurney, R.N. Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat. Rev. Drug Discov. 4, 961-967 (2005).
5. Box, G.E.P. Robustness in the strategy of scientific model building. In Robustness in Statistics (eds. Launer, R.L. & Wilkinson, G.N.) 231-236 (Academic Press, New York, 1979).
6. Cobelli, C., Carson, E.R., Finkelstein, L. & Leaning, M.S. Validation of simple and complex models in physiology and medicine. Am. J. Physiol. 246, R259-R266 (1984).
7. Berman, M. The formulation and testing of models. Ann. NY Acad. Sci. 108, 182-194 (1963).
8. Dollery, C.T. The challenge of complexity. Clin. Pharmacol. Ther. 88, 13-15 (2010).
9. Vicini, P. Multiscale modeling in drug discovery and development: future opportunities and present challenges. Clin. Pharmacol. Ther. 88, 126-129 (2010).
10. Jamei, M. Dickinson, G.L. & Rostami-Hodjegan, A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of "bottom-up" vs. "top-down" recognition of covariates. Drug Metab. Pharmacokinet. 24, 53-75 (2009).
11. Rodriguez, B., Burrage, K., Gavaghan, D., Grau, V., Kohl, P. & Noble, D. The systems biology approach to drug development: application to toxicity assessment of cardiac drugs. Clin. Pharmacol. Ther. 88, 130-134 (2010).
12. McBurney, R.N. et al. The liver toxicity biomarker study: phase I design and preliminary results. Toxicol. Pathol. 37, 52-64 (2009).
13. Adourian, A., et al. Correlation network analysis for data integration and biomarker selection. Mol. BioSyst. 4, 249-259 (2008).
14. Alon, U. An Introduction to Systems Biology: Design Principles of Biological Circuits (Chapman & Hall/CRC, Boca Raton, FL, 2007).
15. Hood, L. & Perlmutter, M. The impact of systems approaches on biological problems in drug discovery. Nat. Biotechnol. 22,1215-1217 (2004).
16. Silver, P.A. & Way, J.C. Molecular systems biology in drug development. Clin. Pharmacol. Ther. 82, 586-590 (2007).
17. Silber, H.E., Jauslin, P.M., Frey, N. & Karlsson, M.O. An integrated model for the glucose-insulin system. Basic Clin. Pharmacol. Toxicol. 106, 189-194 (2009).
18. Berg, J.M., Rogers, M.E. & Lyster, P.M. Systems biology and pharmacology. Clin. Pharmacol. Ther. 88, 17-19 (2010)
19. Sobie, E.A., Jenkins, S.L., Iyengar, R. & Krulwich, T.A. Training in systems pharmacology: predoctoral program in pharmacology and systems biology at Mount Sinai School of Medicine. Clin. Pharmacol. Ther. 88, 19-22 (2010).
20. Allerheiligen, S.R.B. Next-generation model-based drug discovery and development: quantitative and systems pharmacology. Clin. Pharmacol. Ther. 88, 135-137 (2010).